Minerva Neurosciences Announces President's Departure, Executive Payout, and New CBO/General Counsel Appointment
NERV has more than doubled off its 52-week low of $1.15.
Summary
Minerva Neurosciences announced the resignation of its President, Geoffrey Race, effective March 31, 2026, alongside a significant severance package and the appointment of James O'Connor as Chief Business Officer and General Counsel.
Key Events · Executive and Board Changes · NERV
-
President's Resignation
Geoffrey Race resigned as President of Minerva Neurosciences and Director of its subsidiary Mind-NRG, effective March 31, 2026, after 16 years with the company.
-
Substantial Separation Package
The company agreed to a settlement including a cash payout of approximately $676,000, covering annual salary, pension, medical, life assurance, pro-rated bonus, severance, and legal fees.
-
Accelerated Equity Vesting
All of Mr. Race's outstanding stock options were fully vested as of March 31, 2026, with an extended exercise period until January 1, 2030.
-
Consultancy Agreement
Mr. Race will continue to provide consulting services for one year at £333 per hour (minimum 35 hours/month) and may be eligible for additional stock options.
Analysis · NERV · Life Sciences
This filing details a significant leadership transition at Minerva Neurosciences, with the departure of long-serving President Geoffrey Race. The company will incur substantial separation costs, including a cash payout of approximately $676,000 and the immediate vesting of all of Mr. Race's outstanding stock options, which could lead to future dilution. This executive change occurs against a backdrop of the company's challenging financial position, including a massive net loss in 2025 and ongoing drug development delays. The appointment of James O'Connor as Chief Business Officer and General Counsel, along with Mr. Race's continued involvement as a consultant, aims to provide continuity and new leadership, but the overall impact is mixed given the financial implications and the company's current state.
At the time of this filing, NERV was trading at $5.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $228.5M. The 52-week trading range was $1.15 to $12.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.